Merck Millipore and Proteomics International Announce Collaboration for Validation of Biomarkers of Diabetic Nephropathy
Under the collaboration, Proteomics International will assess its thirteen newly identified putative protein biomarkers by using Merck Millipore’s multiplex immunoassays. The biomarkers include proteins involved in metabolism, inflammation, and oxidative stress. Once validated, the biomarkers could be used to monitor the progression and prognosis of kidney disease in patients with diabetes.
Currently, diabetic nephropathy is screened using the microalbumin test, a single biomarker in the urine that has limited utility, however, in predicting and monitoring disease progression. Several of the newly identified biomarkers show promise in enhancing the current screening methods by identifying a signature of biomarkers in the blood that can better represent disease prediction and progression. Proteomics International will also utilize its extensive sample repository of relevant clinical specimens to assess additional biomarkers developed by Merck Millipore.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.